People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sherlock Biosciences, Inc. | — | Biotech / Pharma | Series C | $112.8M | $1.7B | 2022 |
Bryan Dechairo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bryan Dechairo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Rubin | 1 | 8 |
| James Collins | 1 | 8 |
| David Walt | 1 | 6 |
| Issi Rozen | 1 | 2 |
| Rahul Dhanda | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.